SynAct Pharma AB (SYNACT) Earnings Call Transcripts

SynAct Pharma AB's Latest Earnings Call - June 15, 2026

In the second quarter of 2026, SynAct Pharma AB reported promising top-line results from the Phase IIb ADVANCE study for its lead compound, resomelagon, targeting rheumatoid arthritis (RA). The study demonstrated an ACR20 response rate of 76.4% at the 40 mg dose, significantly higher than the 60.8% observed in the placebo group, although the primary endpoint based on DAS28 reduction was not met. Management indicated that these results bolster their confidence in moving towards a Phase III trial and engaging in business development discussions with potential partners. The company is maintaining a strong focus on advancing its clinical program and securing partnerships, particularly in light of the $21 billion U.S. RA drug market.

Reported metrics

Guidance from management

Management signaled confidence in advancing to Phase III trials and engaging in business development discussions, with a focus on securing partnerships and optimizing the project for regulatory readiness.

What management said

We are excited to show the positive top line results of the Phase IIb ADVANCE study. This is a result of several years of hard work and support from investors, colleagues and the rheumatology community. We are very much looking forward to moving the product and the company forward based on these excellent results. I will hand over the presentation to Mads Bjerregaard, CBO of SynAct Pharma.

I think we can agree that the compound is well tolerated, has shown relevant clinical effects during this 12-week study -- I am sorry, in combination with methotrexate. And therefore, it would be logic that the next step would be a longer study to show the full potential of the compounds not only on ACR20, but also on ACR50/70 scores after typically 6 months treatment. So the next step logically would be to go into l...

What analysts pressed on

Analysts expressed concerns regarding the failure to meet the primary endpoint based on DAS28 reduction and the implications for Phase III trial design. There were questions about the higher placebo response rate compared to historical data and how it may affect future studies.

Main topics on the call

• Phase IIb ADVANCE Study Results — The ADVANCE study yielded an ACR20 response rate of 76.4% for the 40 mg dose of resomelagon, compared to 60.8% for placebo. Management stated, "The ADVANCE study delivers this level of performance," indicating strong eff...
• Safety and Tolerability — Resomelagon was reported to have a favorable safety profile with no serious adverse events and no signs of immunosuppression. Management noted, "The compound is very well-tolerated," which is crucial for first-line treat...
• Market Opportunity — Management highlighted the U.S. RA drug market's value exceeding $21 billion, with resomelagon positioned to capture a share by targeting newly diagnosed patients. They believe that the compound could exceed $1 billion i...
• Business Development Strategy — SynAct is prioritizing partnerships for clinical development and commercialization of resomelagon. Management emphasized, "Our priority 1, 2 and 3 are basically to find the right partners to work with us," indicating a s...

Read the full SynAct Pharma AB transcript (June 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 2 SynAct Pharma AB earnings call transcripts on record, spanning March 11, 2026 to June 15, 2026. The most recent call on file is dated June 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SYNACT

Exchange

OM

Country

SE

Sector

Health Care

Industry

Biotechnology

Calls on record

2

First call

March 11, 2026

Most recent

June 15, 2026